Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 26-35 , January 2010

Screening for Chronic Kidney Disease in HIV-Infected Patients

References 

  1. UNAIDS. Report on the global AIDS epidemic. Geneva: UNAIDS; 2006;
  2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005. Centers for Disease Control and Prevention. 17. Atlanta: U.S. Department of Health and Human Services; 2006;
  3. Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953–960
  4. Chow DC, Souza SA, Chen R, et al. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003;4:414–416
  5. Koster JC, Remedi MS, Qiu H, et al. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003;52:1695–1700
  6. Brown T, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med. 2005;165:1179–1184
  7. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–2982
  8. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 1999;100:700–705
  9. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62
  10. Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol. 2005;16:2412–2420
  11. Khan S, Haragsim L, Laszik ZG. HIV-associated nephropathy. Adv Chronic Kidney Dis. 2006;13:307–313
  12. Eggers PW, Kimmel PL. Is there an epidemic of HIV infection in the US ESRD program?. J Am Soc Nephrol. 2004;15:2477–2485
  13. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145–1152
  14. Gardner LI, Holmberg SD, Williamson JM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:203–209
  15. Jones CY, Jones CA, Wilson IB, et al. Cystatin C and creatinine in an HIV cohort: The nutrition for healthy living study. Am J Kidney Dis. 2008;51:914–924
  16. Overton ET, Nurutdinova D, Freeman J, et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009;10:343–350
  17. Fernando SK, Finkelstein FO, Moore BA, et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 2008;355:89–94
  18. Estrella MM, Fine DM, Gallant JE, et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis. 2006;43:377–380
  19. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570
  20. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis. 2004;39:1199–1206
  21. Choi AI, Rodriguez RA, Bacchetti P, et al. Lower rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis. 2007;45:1633–1639
  22. Gupta SK, Mamlin BW, Johnson CS, et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol. 2004;61:1–6
  23. Fine DM, Perazella MA, Lucas GM, et al. Kidney biopsy in HIV: Beyond HIV-associated nephropathy. Am J Kidney Dis. 2008;51:504–514
  24. Sedor JR. Tissue proteomics: A new investigative tool for renal biopsy analysis. Kidney Int. 2009;75:876–879
  25. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  26. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585
  27. Bakir AA, Dunea G. Drugs of abuse and renal disease. Curr Opin Nephrol Hypertens. 1996;5:122–126
  28. Fine DM, Garg N, Haas M, et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol. 2007;2:1125–1130
  29. Freedman BI, Soucie JM, Stone SM, et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis. 1999;34:254–258
  30. Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predicators of risk in the RENAAL study. Diabetes Care. 2003;26:1402–1407
  31. Ejerblad E, Fored CM, Lindblad P, et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol. 2004;15:2178–2185
  32. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290
  33. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7:105–111
  34. Moller CC, Pollak MR, Reiser J. The genetic basis of human glomerular disease. Adv Chronic Kidney Dis. 2006;13:166–173
  35. Russo LM, Sandoval RM, McKee M, et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: Retrieval is disrupted in nephrotic states. Kidney Int. 2007;71:501–513
  36. Kimmel PL, Umana WO, Bosch JP. Abnormal urinary protein excretion in HIV-infected patients. Clin Nephrol. 1993;39:17–21
  37. Busch HW, Riechmann S, Heyen P, et al. Albuminuria in HIV-infected patients. AIDS Res Hum Retroviruses. 1994;10:717–720
  38. Zandi-Nejad K, Eddy AA, Glassock RJ, et al. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl. 2004;92:S76–S89
  39. Siedner MJ, Atta MG, Lucas GM, et al. Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndrom. 2008;47:261–263
  40. Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983;309:1543–1546
  41. Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem. 2005;51:1577–1586
  42. Nguyen MT, Maynard SE, Kimmel PL. Misapplications of commonly used kidney equations: Renal physiology in practice. Clin J Am Soc Nephrol. 2009;4:528–534
  43. Gaspari F, Perico N, Remuzz G. Measurement of glomerular filtration rate. Kidney Int Suppl. 1997;63:S151–S154
  44. Levey AS. Measurement of renal function in chronic renal disease (clinical conference). Kidney Int. 1990;38:167–184
  45. Verhave JC, Fesler P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: Influence of age and body mass index. Am J Kidney Dis. 2005;46:233–241
  46. Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis. 2002;39:920–929
  47. Ross JW, Miller WG, Myers GL, et al. The accuracy of laboratory measurements in clinical chemistry: A study of 11 routine chemistry analytes in the College of American Pathologists Chemistry Survey with fresh frozen serum, definitive methods, and reference methods. Arch Pathol Lab Med. 1998;122:587–608
  48. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  49. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470
  50. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:115A
  51. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–772
  52. Coresh J, Stevens LA. Kidney function estimating equations: where do we stand?. Curr Opin Nephrol Hypertens. 2006;15:276–284
  53. Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–937
  54. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol. 2002;13:2140–2144
  55. Lin J, Knight EL, Hogan ML, et al. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003;14:2573–2580
  56. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612
  57. Roy MT, First MR, Myre SA, et al. Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in normal subjects. Ther Drug Monit. 1982;4:77–79
  58. Maia BS, Engelson ES, Wang J, et al. Antiretroviral therapy affects the composition of weight loss in HIV infection: Implications for clinical nutrition. Clin Nutr. 2005;24:971–978
  59. Huang E, Hewitt RG, Shelton M, et al. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy. 1996;16:222–229
  60. Noormohamed SE, Katseres JK, Stapleton JT. Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Ren Fail. 1998;20:627–633
  61. Smith BL, Sarnoski TP, Dennis S, et al. Failure of predicted creatinine clearance equations in HIV-seropositive patients. Int J Clin Pharmacol Ther Toxicol. 1992;30:394–399
  62. Barraclough K, Er L, Ng F, et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract. 2009;111:c39–c48
  63. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis. 2002;40:221–226
  64. Laterza OF, Price CP, Scott MG, Cystatin C. An improved estimator of glomerular filtration rate?. Clin Chem. 2002;48:699–707
  65. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992;38(suppl 1):S20–S27
  66. Kottgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2008;51:385–394
  67. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009;75:652–660
  68. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–1421
  69. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008;3:348–354
  70. O'Riordan SE, Webb MC, Stowe JH, et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem. 2003;40:648–655
  71. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29–34
  72. Christensson AG, Grubb A, Nilsson JA, et al. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but no severe diabetic nephropathy. J Intern Med. 2004;256:510–518
  73. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406
  74. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin C and prognosis of cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–246
  75. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049–2060
  76. Larsson A, Helmersson J, Hansson LO, et al. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest. 2005;65:301–305
  77. Odden MC, Scherzer R, Bacchetti P, et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: The FRAM study. Arch Intern Med. 2007;167:2213–2219
  78. Mocroft A, Wyatt C, Szczech L, et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS. 2009;23:71–82
  79. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296
  80. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17:127–132
  81. Yang J, Mori K, Li JY, Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol. 2003;285:F9–F18
  82. Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant. 2008;23:414–416
  83. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:337–344
  84. Soler-Garcia AA, Johnson D, Hathout Y, et al. Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases. Clin J Am Soc Nephrol. 2009;4:763–771
  85. Landro L, Damas JK, Flo TH, et al. Decreased serum lipocalin-2 levels inhuman immunodeficiency virus-infected patients: Increase during highly active anti-retroviral therapy. Clin Exp Immunol. 2008;152:57–63
  86. Borregaard N, Sehested M, Nielsen BS, et al. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood. 1995;85:812–917
  87. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochem Biophys Acta. 2000;1482:298–307
  88. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26:136–142
  89. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449–2455
  90. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimetholarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456–2461
  91. Kamijo A, Sugaya T, Hikawa A, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175–182

 Dr. Estrella is supported by the NIH/NIDDK grant 1K23DK081317-01A1. Dr. Fine has received consulting fees and speaker honoraria from GlaxoSmithKline

PII: S1548-5595(09)00150-5

doi: 10.1053/j.ackd.2009.07.014

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 26-35 , January 2010

Article Tools

* Image Usage & Resolution